UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Quality-of-life outcomes in metastatic spinal cord compression: findings from the SCORAD trial

Hoskin, Peter J; Reczko, Krystyna; Rashid, Memuna; Hackshaw, Allan; Lopes, Andres; SCORAD Investigators; (2024) Quality-of-life outcomes in metastatic spinal cord compression: findings from the SCORAD trial. JNCI: Journal of the National Cancer Institute , Article djae039. 10.1093/jnci/djae039. (In press).

[thumbnail of Hackshaw_SCORAD QoL 3.0 - Manuscript_REV -no tracking.pdf] Text
Hackshaw_SCORAD QoL 3.0 - Manuscript_REV -no tracking.pdf
Access restricted to UCL open access staff until 6 May 2025.

Download (283kB)

Abstract

Purpose: This article reports detailed quality-of-life data including preferred and actual place of care from SCORAD, the only large prospective randomized trial in metastatic spinal cord compression (MSCC). // Methods: SCORAD compared 2 doses of radiotherapy in patients with MSCC: 8 Gy single fraction and 20 Gy in 5 fractions. In total, 686 patients were randomized, of whom 590 had Health-Related Quality of Life (HRQoL) data collected at baseline and at least 1 later time point. HRQoL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 supplemented with the QLU-C10D and data on place of care at weeks 1, 4, 8, and 12 postrandomization. Quality-of-Life Adjusted Survival was computed by multiplying Kaplan-Meier survival probabilities with the UK utility weights obtained from the QLU-C10D. // Results: Patients with a baseline physical functioning score of above 50 demonstrated a 28% reduction in the risk of death (hazard ratio [HR] = 0.72, 99% confidence interval [CI] = 0.54 to 0.95; P = .003). An increased risk of death was associated with fatigue (HR = 1.35, 99% CI = 1.03 to 1.76; P = .0040), dyspnea (HR = 1.61, 99% CI = 1.24 to 2.08; P < .001), and appetite loss (HR = 1.25, 99% CI = 0.99 to 1.59; P = .014). The preferred place of care for the majority was at home or with relatives (61%-74% across the 12 weeks) but achieved by only 53% at 8 weeks. // Conclusions: Prolonged survival in patients with MSCC was associated with better HRQoL. More than 60% of patients preferred to be cared for at home or with relatives, but only half were able to achieve this. There was no difference in HRQoL between the multifraction and single-fraction groups. // Trial registration: ISRCTN97555949 and ISRCTN97108008.

Type: Article
Title: Quality-of-life outcomes in metastatic spinal cord compression: findings from the SCORAD trial
Location: United States
DOI: 10.1093/jnci/djae039
Publisher version: http://dx.doi.org/10.1093/jnci/djae039
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
URI: https://discovery.ucl.ac.uk/id/eprint/10192294
Downloads since deposit
2Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item